News

Mycophenolate Mofetil Can Replace Cyclophosphamide at Inducing Remission in Some AAV Patients, Clinical Trial Suggests

The immunosuppressant agent mycophenolate mofetil (MMF) is similar to standard cyclophosphamide at inducing remission in ANCA-associated vasculitis (AAV) patients, but it seems to be associated with a higher relapse rate, a clinical trial shows. The findings suggest that MMF is a potential alternative to cyclophosphamide, particularly in patients…

Patient Develops AAV Due to Familial Mediterranean Fever, Case Study Shows

Blood vessel inflammation caused by ANCA antibodies should be considered in the differential diagnosis of familial Mediterranean fever with hyperthyroidism, a case study shows. The study, “Antineutrophil cytoplasmic antibody-positive familial Mediterranean fever and hyperthyroidism: A case report,” was published in the journal Medicine. Familial Mediterranean…

Omalizumab May Reduce Asthma Symptoms and Steroid Requirement in EGPA Patients, Study Shows

Omalizumab, an injectable medication approved for allergic asthma, might reduce asthma symptoms and steroid dosages in patients with eosinophilic granulomatosis with polyangiitis (EGPA), according to a retrospective study. The study, “Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) single-center experience in 18 cases,” was published in …

European Union Approves Phase 2 Trial Testing IFX-1 in AAV Patients

InflaRx will soon launch a Phase 2 clinical trial in Europe to assess the safety and effectiveness of IFX-1 — an investigational inhibitor of the complement system — in patients with ANCA-associated vasculitis (AAV). Now that European authorities have approved it, the randomized, placebo-controlled Phase 2 trial is expected to recruit approximately…